 Life Science Events, Jobs, Directory, News  SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux’s TRACTr platform, targeting an undisclosed solid tumor antigen expr
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. |